Myriad Genetics Publishes Meta-Analysis Of 3,532 MDD Patients Showing GeneSight Psychotropic Test Improves Response And Remission Rates Vs. Standard Treatment

Author: Benzinga Newsdesk | September 03, 2025 04:33pm

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight® Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual (TAU).

Specifically, compared to TAU, patients in the GeneSight arm were:

• 41% more likely to achieve remission.
• 30% more likely to achieve response.

Myriad Genetics plans to submit this data to payers as part of ongoing efforts to increase patient access to the GeneSight test and help patients achieve remission from depression.

Posted In: MYGN